Baxalta
is developing, manufacturing and commercializing therapies for orphan diseases... Read moreBaxalta
is developing, manufacturing and commercializing therapies for orphan diseases... Read more
CEO
Add
News
Nov 02, 2017
PharmiWeb
Baxalta: Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc
Jul 18, 2017
Business Insider
Baxalta: Here's how the CEO of a $50 billion drugmaker sees tech companies 'disrupting' healthcare (SHGP)
Jul 16, 2017
Business Insider
Baxalta: The CEO of a $50 billion company explains why investment bankers are moaning 'about the tough times they're going through' (SHGP)
May 05, 2017
BioPharma-Reporter
Baxalta: Shire using Baxalta network to bring 30% Cinryze production in-house
May 02, 2017
4-traders
Baxalta: Baxalta : London-listed Shire looking fit as sales rise
Apr 28, 2017
BioPortfolio
Baxalta: Baxalta Inc Pharmaceuticals Healthcare Deals and Alliances Profile Updated 23022017 Prices from USD $250
Apr 18, 2017
BioPortfolio
Baxalta: Baxalta Inc Pharmaceuticals Healthcare Deals and Alliances Profile Updated 10032017 Prices from USD $250
Mar 23, 2017
BioPortfolio
Baxalta: SuppreMol GmbH Pharmaceuticals Healthcare Deals and Alliances Profile Updated 24022017 Prices from USD $250
Nov 01, 2016
BioPortfolio
Baxalta: Shire shares slip as sales miss estimates in first full quarter with Baxalta
Oct 25, 2016
NewsMaker
Press Release: Baxalta :
Hemophilia Drugs Market - Industry Challenges, Key Vendors, Drivers, Trends and Forecast to 2020
Baxalta Competitors
1
2
3
4
5
6
7
8
9
10